Skip to content

Gilead Sciences

American biopharmaceutical company developing and commercializing medicines for viral infections, cancer, inflammation, and other serious diseases.

Last updated November 15, 2026

AI crawler reads

141requests

7AI
  • OpenAI83
  • Perplexity20
  • Shape13
  • Amazon10
  • Anthropic7
  • +28
Profile
89
Controversies
19
JSON · MD
0
First read
Oct 29, 2026
Latest read
Nov 17, 2026

From this site's server log

Overview

Gilead Sciences is an American biopharmaceutical company headquartered in Foster City, California. Founded in 1987 by physician and investor Michael L. Riordan, the company began as Oligogen, a name reflecting its early interest in oligonucleotides and antisense approaches to targeting genetic sequences. It later adopted the Gilead Sciences name and concentrated increasingly on small-molecule antiviral medicines. That decision shaped the company’s identity and ultimately made it one of the most influential specialist pharmaceutical companies in HIV, hepatitis, and infectious disease. Gilead’s early development work included nucleotide analogues licensed from European academic institutions. These compounds led to medicines such as cidofovir, tenofovir, and adefovir, marketed respectively as Vistide, Viread, and Hepsera. The company went public on NASDAQ in 1992. Its acquisition of NeXstar Pharmaceuticals in 1999 added commercial infrastructure, AmBisome, and DaunoXome, while also giving Gilead a larger international sales organization. Gilead’s discovery of oseltamivir and its licensing arrangement with Roche produced Tamiflu, which became an important influenza medicine and generated substantial demand during avian-influenza and pandemic-preparedness periods. During the 2000s, Gilead developed from a venture-backed biotechnology start-up into a vertically broader pharmaceutical business. Viread, Emtriva, and combination products helped establish a major HIV franchise. In 2002 the company refocused its corporate strategy on antiviral medicines and sold certain cancer assets, but later returned to oncology and other therapeutic areas through acquisitions and internal research. Acquisitions of Triangle Pharmaceuticals, Corus Pharma, Myogen, CV Therapeutics, and other companies expanded its positions in HIV, respiratory disease, pulmonary hypertension, cardiovascular medicine, and research chemistry. The acquisition of Pharmasset in 2011 was a decisive turning point. It brought sofosbuvir into Gilead’s portfolio, leading to Sovaldi and Harvoni, direct-acting antiviral medicines that transformed treatment of hepatitis C and achieved very high cure rates in many patients. Their launch also generated intense public and political criticism over United States pricing, access, and the gap between list prices and manufacturing costs. Gilead subsequently broadened its portfolio through acquisitions and partnerships in oncology, inflammation, liver disease, and cell therapy. The 2017 purchase of Kite Pharma marked Gilead’s major entry into cellular immunotherapy. Kite’s Yescarta became one of the first commercially available CAR-T therapies in the United States for certain blood cancers. Gilead has since combined its antiviral base with oncology and cell-therapy research, including medicines and programs associated with Kite and Immunomedics. Its portfolio includes HIV treatments and prevention products such as Biktarvy and Truvada, hepatitis therapies, oncology products, cell therapies, and treatments for selected inflammatory, pulmonary, and liver disorders. During the COVID-19 pandemic, remdesivir, marketed as Veklury, became a prominent Gilead product after regulatory authorization for specified hospitalized patients. Gilead operates through research, clinical development, regulatory, manufacturing, licensing, and commercial activities. It continues to rely in part on external manufacturing partners while maintaining internal scientific, development, and commercial capabilities. The company’s stated public-health priorities include HIV prevention and treatment, viral hepatitis elimination, oncology, cell therapy, and addressing diseases with substantial unmet medical need. Its record combines major therapeutic breakthroughs with continuing debate about drug pricing, patent rights, access programs, and corporate responsibility.

History

Gilead Sciences was established in 1987 in Foster City, California, by Michael L. Riordan. Its early research centered on antiviral chemistry and nucleotide-based medicines. The company’s first major commercial products included Vistide, approved in 1996 for cytomegalovirus retinitis in certain patients with AIDS, and the influenza medicine Tamiflu, which Gilead discovered and later licensed to Roche for development and commercialization. Gilead’s 1992 initial public offering provided capital for research and development. In 1999, it acquired NeXstar Pharmaceuticals, gaining products including AmBisome and DaunoXome as well as a broader international commercial infrastructure. During the early 2000s, Gilead narrowed its strategic emphasis toward antivirals and sold its cancer assets to OSI Pharmaceuticals. It acquired Triangle Pharmaceuticals in 2002, obtaining emtricitabine, an important component of subsequent HIV combination products. The HIV franchise became the company’s central growth engine. Gilead developed or commercialized combinations containing tenofovir and emtricitabine, including Truvada and later single-tablet regimens. Products such as Atripla, Complera, Stribild and Genvoya simplified treatment for many patients. In 2012, Truvada received U.S. approval for HIV pre-exposure prophylaxis, creating a second major use and making the product important in public-health prevention programs. Descovy was subsequently approved for treatment and, in 2019, for PrEP in specified populations. Gilead entered a transformative phase in hepatitis C with the acquisition of Pharmasset in 2012. Sovaldi, followed by Harvoni and Epclusa, helped establish short-course, all-oral hepatitis C treatment as a new standard for many patients. The clinical impact was substantial, but high list prices led to disputes involving governments, insurers, patient advocates and public-health organizations. Gilead responded through access programs, licensing arrangements and commercial changes, while competition and generic entry later altered the market. The company expanded its scientific and commercial base through acquisitions and partnerships. The 2017 acquisition of Kite Pharma brought Yescarta, a CAR-T therapy, into Gilead and made cell therapy a core strategic area. Gilead also developed remdesivir, marketed as Veklury, which received emergency and later regulatory authorizations for eligible patients with COVID-19. In 2020, Gilead acquired Immunomedics for approximately $21 billion, adding Trodelvy and accelerating its move into oncology. In the 2020s, Gilead’s portfolio combined a mature but durable HIV business with oncology, cell therapy and immunology research. The company continued marketing medicines such as Biktarvy, Descovy, Yescarta, Tecartus, Trodelvy and Veklury while investing in clinical-stage programs and external collaborations. Its history illustrates the evolution of a specialist antiviral biotechnology company into a diversified global biopharmaceutical business.

  • 2020

    Immunomedics acquisition completed

    [3]

    Gilead completed the acquisition of Immunomedics and added Trodelvy to its oncology portfolio.

  • 2017

    Kite acquisition

    [1]

    Gilead acquired Kite Pharma and entered commercial CAR-T cell therapy through Yescarta.

  • 2012

    Truvada approved for PrEP

    [4]

    The U.S. FDA approved Truvada to reduce the risk of sexually acquired HIV infection in eligible individuals.

  • 2012

    Pharmasset acquisition

    [1]

    Gilead acquired Pharmasset, obtaining the hepatitis C program that led to Sovaldi and related therapies.

  • 2002

    Antiviral strategy sharpened

    [1]

    Gilead adopted an exclusive antiviral focus and sold its cancer assets to OSI Pharmaceuticals.

  • 1999

    NeXstar acquisition

    [1]

    The acquisition expanded Gilead’s product portfolio and international commercial capabilities.

  • 1996

    Vistide launch

    [1]

    Vistide was launched for cytomegalovirus retinitis in certain patients with AIDS.

  • 1992

    Initial public offering

    [1]

    Gilead began trading publicly on Nasdaq.

  • 1987

    Company founded

    [1]

    Michael L. Riordan founded Gilead Sciences in California to develop antiviral medicines.

Products and positioning

A research-driven global biopharmaceutical company with historic leadership in HIV and hepatitis therapeutics and an expanding oncology and cell-therapy platform.

  • HIV treatment · 2018

    Biktarvy

    Biktarvy is a once-daily single-tablet HIV treatment combining bictegravir, emtricitabine and tenofovir alafenamide. Gilead has marketed it as a modern treatment option and used patient-centered campaigns emphasizing that people living with HIV can continue pursuing ordinary relationships, work and personal goals.

  • HIV treatment and prevention · 2016

    Descovy

    Descovy combines emtricitabine and tenofovir alafenamide. It is used for HIV treatment in combination with other antiretroviral agents and was later approved for PrEP in specified populations. Its prevention marketing positioned it as a newer option from the makers of Truvada.

  • HIV treatment and PrEP · 2004

    Truvada

    Truvada combines emtricitabine and tenofovir disoproxil fumarate. It became a foundational Gilead HIV product and, after its 2012 PrEP approval, one of the best-known medicines for preventing sexual transmission of HIV in eligible people.

  • Hepatitis C treatment · 2014

    Harvoni

    Harvoni is an oral fixed-dose combination of ledipasvir and sofosbuvir for hepatitis C. Gilead promoted it through campaigns focused on patients seeking treatment and the possibility of cure after years of living with infection.

  • Hepatitis C treatment · 2016

    Epclusa

    Epclusa combines sofosbuvir and velpatasvir and was designed to treat chronic hepatitis C across genotypes. Gilead’s Your Kind of Cure campaign highlighted the medicine’s broad genotype coverage and different patient circumstances.

  • CAR-T cell therapy · 2017

    Yescarta

    Yescarta is an autologous CAR-T cell therapy developed through Gilead’s Kite subsidiary. It reprograms a patient’s T cells to recognize certain blood-cancer targets and represents Gilead’s major commercial entry into cellular immunotherapy.

  • Oncology antibody-drug conjugate · 2020

    Trodelvy

    Trodelvy is an antibody-drug conjugate added through the Immunomedics acquisition. It delivers a cytotoxic payload to cells expressing Trop-2 and became a central asset in Gilead’s effort to build a broader oncology business.

  • COVID-19 antiviral · 2020

    Veklury

    Veklury is the commercial name for remdesivir, an intravenous antiviral used for eligible patients with COVID-19 under applicable regulatory guidance. It became Gilead’s most prominent respiratory-virus product during the COVID-19 pandemic.

Controversies

  • 2024

    Gilead discontinues ENHANCE-3 after interim analysis

    Gilead discontinued the phase 3 ENHANCE-3 trial of magrolimab combined with venetoclax and azacitidine after an independent monitoring committee's interim overall-survival analysis found futility and an increased risk of death, mainly driven by respiratory failure and infections. Patients will discontinue magrolimab treatment.

  • 2022

    Dispute over 340B contract-pharmacy restrictions

    AIDS Healthcare Foundation publicly accused Gilead of unlawfully restricting access to certain medicines through 340B contract pharmacies and used the term “Greediad” in advocacy advertising. The supplied source documents the organization’s allegations and campaign, not a final legal determination.

  • 2022

    Düsseldorf court rules Gilead sofosbuvir infringes NuCana patent

    NuCana reported that the Regional Court of Düsseldorf issued a judgment that Gilead's sofosbuvir infringes NuCana's European composition-of-matter patent.

  • 2021

    Patients sue Gilead over alleged toxicity and disclosure of HIV drug risks

    Patients with HIV brought a civil suit against Gilead, accusing the company of failing to properly report potential health effects of its HIV drugs and alleging that the drugs caused kidney and bone problems. The claims are allegations by the plaintiffs, not a court determination.

  • 2020

    Gilead responds to questions about remdesivir trials and patents

    Gilead issued a statement addressing questions about remdesivir, saying it had reached an agreement with Chinese health authorities to support two clinical trials and that it holds patents for the drug in China, the United States and elsewhere. It also said the China patent application for coronavirus use was pending approval.

  • 2019

    U.S. government sues Gilead over PrEP patent rights

    In a legal dispute involving Gilead Sciences, the U.S. Department of Health and Human Services filed a lawsuit concerning patent rights to Truvada and Descovy for HIV prevention. The suit asserts that the government owns the relevant PrEP patents. These claims are allegations made in the litigation and do not constitute a court determination. The event concerns a patent dispute over HIV prevention drugs and the asserted ownership of PrEP-related patents.

Read more

Brand decisions

  • 2026

    Gilead announces acquisition of PepStar oral inflammation drug programM&A

    Background

    Gilead said it would acquire PepStar Therapeutics’ oral inflammation drug program for a $1.275 billion cash upfront payment. The program includes an experimental treatment for intestinal disease.

  • 2024

    Gilead completes acquisition of CymaBay TherapeuticsM&A

    Background

    Gilead Sciences announced that it completed the acquisition of CymaBay Therapeutics for around $4.3 billion. CymaBay now operates as a fully owned Gilead subsidiary, and its common stock is no longer available for trading on Nasdaq.

  • 2022

    Gilead agrees to acquire MiroBioM&A

    Background

    Medicxi announced that MiroBio had entered into a definitive agreement to be acquired by Gilead Sciences for approximately $405 million in cash, subject to customary adjustments. The acquisition was an agreement, not a reported completion.

  • 2022

    Gilead completes acquisition of MiroBioM&A

    Background

    Gilead announced that it completed its acquisition of privately held U.K.-based biotechnology company MiroBio for approximately $405 million in cash. The acquisition included MiroBio's discovery platform and portfolio of immune inhibitory receptor agonists.

  • 2021

    Gilead completes acquisition of MYR GmbHM&A

    Background

    Gilead Sciences announced completion of its acquisition of MYR GmbH for up to approximately €1.45 billion in aggregate cash consideration. MYR became a wholly owned subsidiary of Gilead.

  • 2020

    Gilead completes acquisition of ImmunomedicsM&A

    Background

    Gilead completed its acquisition of Immunomedics for approximately $21 billion. Immunomedics became a wholly owned subsidiary of Gilead, and its common stock was to cease trading on Nasdaq.

  • 2020

    Gilead announced its acquisition of ImmunomedicsM&A

    Background

    Gilead announced it would acquire biotechnology company Immunomedics for $21 billion, with the deal expected to close in the fourth quarter of 2020.

  • 2020

    Gilead Sciences announces agreement to acquire Forty SevenM&A

    Background

    Gilead Sciences and Forty Seven announced a definitive agreement under which a Gilead subsidiary will acquire all outstanding common shares of Forty Seven for $95.50 per share in cash, valuing the deal at approximately $4.9 billion. Completion was expected during the second quarter of 2020, subject to regulatory approval and other transaction details.

  • 2020

    Gilead announces acquisition of MYRM&A

    Background

    Gilead announced an all-cash deal to acquire German biopharmaceutical company MYR for 1.15 billion euros. The transaction was expected to close in the first quarter of the following year; completion had not yet occurred in the report.

  • 2020

    Gilead completes acquisition of Forty SevenM&A

    Background

    Gilead announced completion of the acquisition of Forty Seven by a Gilead subsidiary. Forty Seven became a wholly owned subsidiary of Gilead, and its common stock would no longer be listed for trading on the Nasdaq Global Select Market.

Recent events

  • Gilead announces acquisition of PepStar oral inflammation drug program[5]

    Reported

    Gilead said it would acquire PepStar Therapeutics’ oral inflammation drug program for a $1.275 billion cash upfront payment. The program includes an experimental treatment for intestinal disease.

  • FDA approves expanded pediatric indication for Vemlidy[24]

    Reported

    The US Food and Drug Administration approved Gilead Sciences’ supplemental new drug application for Vemlidy to treat chronic hepatitis B in certain pediatric patients.

  • Gilead completes acquisition of CymaBay Therapeutics[6]

    Reported

    Gilead Sciences announced that it completed the acquisition of CymaBay Therapeutics for around $4.3 billion. CymaBay now operates as a fully owned Gilead subsidiary, and its common stock is no longer available for trading on Nasdaq.

  • Gilead discontinues ENHANCE-3 after interim analysis[21]

    Reported

    Gilead discontinued the phase 3 ENHANCE-3 trial of magrolimab with venetoclax and azacitidine after an independent monitoring committee's interim overall-survival analysis found futility and an increased risk of death, mainly driven by respiratory failure and infections. Patients will discontinue magrolimab treatment.

  • Gilead and Compugen announce exclusive antibody-program license[25]

    Reported

    Gilead Sciences announced an agreement with Compugen to exclusively license Compugen’s pre-clinical antibody program against IL-18 binding protein, including the COM503 drug candidate. Gilead will make an immediate $60 million payment, with potential additional milestone payments and royalties described in the agreement.

  • Gilead and Assembly Biosciences enter antiviral research partnership[26]

    Reported

    Gilead Sciences and Assembly Biosciences entered into a 12-year partnership to advance research and development of antiviral therapies, initially focused on herpesviruses, hepatitis B virus and hepatitis D virus.

  • Gilead expands IT partnership with Cognizant[27]

    Reported

    Gilead Sciences expanded its collaboration with Cognizant through a new five-year service agreement worth approximately $800 million. Cognizant will manage Gilead’s global IT infrastructure, platforms, applications and advanced analytics.

  • Gilead discontinues ENHANCE trial[28]

    Reported

    Gilead Sciences announced the discontinuation of the phase 3 ENHANCE trial evaluating magrolimab plus azacitidine in higher-risk MDS after a planned analysis found the trial futile. The company recommended stopping magrolimab treatment for enrolled patients, and investigators and the company were evaluating next steps for them.

  • FDA approves expanded Veklury use for patients with severe renal impairment[29]

    Reported

    The U.S. Food and Drug Administration approved a supplemental application for Veklury (remdesivir) to treat COVID-19 patients with severe renal impairment, including patients on dialysis, Gilead Sciences said.

  • FDA approves Sunlenca for certain adults with HIV-1[30]

    Reported

    The U.S. Food and Drug Administration approved Gilead Sciences' Sunlenca (lenacapavir) for adults living with HIV-1 whose infections cannot be successfully treated with other available treatments because of resistance, intolerance, or safety considerations.

Read more(47)

Sources66 sources

  1. 1Gilead Sciencesen.wikipedia.org
  2. 2Gilead Sciences corporate leadershipgilead.com
  3. 3Gilead Sciences completes acquisition of Immunomedicsgilead.com
  4. 4Gilead launches PrEP awareness advertisingnbcnews.com
  5. 5Gilead announces acquisition of PepStar oral inflammation drug programfinance.jrj.com.cn
  6. 6Gilead completes acquisition of CymaBay Therapeuticsfinanznachrichten.de
  7. 7Gilead agrees to acquire MiroBioprnewswire.com
  8. 8Gilead completes acquisition of MiroBiofinanznachrichten.de
  9. 9Gilead completes acquisition of MYR GmbHinvestingnews.com
  10. 10Gilead completes acquisition of Immunomedicsinvestingnews.com
  11. 11Gilead announced its acquisition of Immunomedicstech.sina.com.cn
  12. 12Gilead Sciences announces agreement to acquire Forty Sevenfinance.sina.com.cn
  13. 13Gilead announces acquisition of MYRfinance.sina.com.cn
  14. 14Gilead completes acquisition of Forty Sevenfinance.sina.com.cn
  15. 15Dispute over 340B contract-pharmacy restrictionsbusinesswire.com
  16. 16U.S. government sues Gilead over PrEP patent rightsnbcnews.com
  17. 17U.S. government sues Gilead over PrEP patent rightsmedscape.com
  18. 18U.S. government sues Gilead over PrEP patent rightslawstreetmedia.com
  19. 19U.S. government sues Gilead over PrEP patent rightsstatnews.com
  20. 20Gilead responds to questions about remdesivir trials and patentsfinance.sina.com.cn
  21. 21Gilead discontinues ENHANCE-3 after interim analysisonclive.com
  22. 22Düsseldorf court rules Gilead sofosbuvir infringes NuCana patentfinanznachrichten.de
  23. 23Patients sue Gilead over alleged toxicity and disclosure of HIV drug riskslawstreetmedia.com
  24. 24FDA批准Vemlidy扩展儿童适应症pharmaceutical-business-review.com
  25. 25Gilead 与 Compugen 宣布抗体项目独家许可协议en.globes.co.il
  26. 26吉利德与Assembly Biosciences达成抗病毒研究合作finanznachrichten.de
  27. 27Gilead扩大与Cognizant的IT合作pmlive.com
  28. 28吉利德停止 ENHANCE 试验ajmc.com
  29. 29FDA批准Veklury用于严重肾功能损害患者finanznachrichten.de
  30. 30FDA批准Sunlenca用于部分HIV-1成年患者finanznachrichten.de
  31. 31吉利德承诺资助猴痘教育foxnews.com
  32. 32Curebase 完成 4,000 万美元 B 轮融资prnewswire.com
  33. 33吉利德宣布在爱尔兰设立儿科药物开发中心fiercebiotech.com
  34. 34Gilead 支持扩大印度本地瑞德西韦生产thepharmaletter.com
  35. 35吉利德科学宣布比尔·李退休investingnews.com
  36. 36吉利德推出种族平等社区影响基金investingnews.com
  37. 37ProteoNic向Gilead Sciences授予2G UNic技术许可prnewswire.com
  38. 38FDA批准Veklury用于治疗COVID-19foxla.com
  39. 39吉利德与Tango扩大癌症疗法合作finance.yahoo.com
  40. 40吉利德上调2020年销售额预期business-standard.com
  41. 41吉利德公布瑞德西韦价格ibtimes.co.uk
  42. 42Hetero在印度推出Coviforthehindu.com
  43. 43Gilead与Arcus签署肿瘤合作协议pharmaceutical-business-review.com
  44. 44Cipla与吉利德科学签署瑞德西韦非独家许可协议business-standard.com
  45. 45FDA授权Gilead的瑞德西韦紧急使用independent.co.uk
  46. 46FDA批准Epclusa用于儿童丙型肝炎治疗healio.com
  47. 47吉利德同意支持瑞德西韦在中国开展临床试验sc.stock.cnfol.com
  48. 48吉利德科学宣布任命安德鲁·迪金森为首席财务官finanznachrichten.de
  49. 49FDA 批准 Descovy 用于 HIV 预防nbcnews.com
  50. 50抗疫药瑞德西韦走热 吉利德回应临床实验、专利等质疑ip.people.com.cn
  51. 51FDA Approves First COVID Treatment, Gilead's Remdesivir Drugibtimes.com
  52. 52FDA approves Gilead Sciences’ HIV PrEP drug Descovypharmaceutical-business-review.com
  53. 53FDA Approves Gilead's Remdesivir as Coronavirus Treatmentnbclosangeles.com
  54. 54FDA Approves Gilead's Remdesivir To Treat Young Children With COVID-19finanznachrichten.de
  55. 55FDA approves Gilead's remdesivir, first drug for treating COVID-19fox5ny.com
  56. 56FDA approves Veklury as first antiviral COVID-19 treatment for all liver disease stageshealio.com
  57. 57Gilead acquires IBD treatment with $1.275bn PepStar acquisitionbioxconomy.com
  58. 58Gilead appoints new chief financial officer - PharmaTimespharmatimes.com
  59. 59Gilead completes acquisition of MiroBio in $405m cash deal - PMLiVEpmlive.com
  60. 60Gilead Sciences Appoints Deborah Telman as Executive Vice President Corporate Affairs and General Counselgilead.com
  61. 61Gilead Unit Completes Acquisition Of Forty Sevenfinanznachrichten.de
  62. 62Government Sues Gilead Over Truvada Patent & Royaltiesavn.com
  63. 63HHS Sues Drugmaker Gilead Over PrEP Patent Infringementnpr.org
  64. 64U.S. Government Hits HIV Drug Manufacturer With Patent Complaintscrippsnews.com
  65. 65US Government Sues Gilead for HIV Drug Patent Infringement – Gay City Newsgaycitynews.com
  66. 66What We're Reading: Gilead Sued Over PrEP; Seasonal Workers and Medicaid; Preventable Deaths | AJMCajmc.com

Cite this profile: Cite the canonical profile. /brandpedia/gilead · Editorial policy · How profiles are compiled